Introduction: Murray sputum colour chart stratifies patients according to the presence of mucous (M), muco-purulent (MP) or purulent (P) sputum, and has not been validated in Bx yet. We aimed to validate this scale across a large Italian cohort of Bx patients. Methods: A secondary analysis of the IRIDE database was conducted including adults with Bx and daily sputum production enrolled across 13 Italian centres between 2014 and 2017. M vs. MP vs. P sputum producers were identified and clinical, functional and microbiological data were collected. Clinical outcomes during a two-year follow up period were evaluated in the Monza and Milan cohorts. A sensitivity analysis excluding COPD patients was conducted. Results: 448 patients were enrolled (65% female, median age 68 years): 45% belonged to Group M, 40% to Group MP and 15% to Group P. Significant differences (M vs. MP vs. P) were detected in terms of rate of chronic infection due to any bacteria (30% vs. 47% vs. 71%, p<0.001), P. aeruginosa (20% vs. 32% vs. 58%, p<0.001) and other bacteria (14% vs 19% vs 25%, p=0.038). Median predicted FEV1 was statistically different among the groups (M:88% vs. MP:77% vs. P:72%, p<0.001) as well as the median Bronchiectasis Severity Index values (M:6 vs. MP:8 vs. P:9, p<0.001). Quality of life was significantly poorer in Group P vs. MP vs. M (QoL-B respiration score: 52 vs. 61 vs. 70, p<0.001). Differences in hospitalization rate (M: 10% vs P: 33%) and 3+ exacerbation/year (M 41% vs P 58%) were detected in follow up. The exclusion of COPD did not affect the results. Conclusion: Murray sputum chart is a valuable tool to assess disease severity and might be useful to predict clinical outcomes in Bx.
Validation of Murray sputum purulence scale in the Italian Registry of Bronchiectasis (IRIDE)
Cecilia Calabrese;
2018
Abstract
Introduction: Murray sputum colour chart stratifies patients according to the presence of mucous (M), muco-purulent (MP) or purulent (P) sputum, and has not been validated in Bx yet. We aimed to validate this scale across a large Italian cohort of Bx patients. Methods: A secondary analysis of the IRIDE database was conducted including adults with Bx and daily sputum production enrolled across 13 Italian centres between 2014 and 2017. M vs. MP vs. P sputum producers were identified and clinical, functional and microbiological data were collected. Clinical outcomes during a two-year follow up period were evaluated in the Monza and Milan cohorts. A sensitivity analysis excluding COPD patients was conducted. Results: 448 patients were enrolled (65% female, median age 68 years): 45% belonged to Group M, 40% to Group MP and 15% to Group P. Significant differences (M vs. MP vs. P) were detected in terms of rate of chronic infection due to any bacteria (30% vs. 47% vs. 71%, p<0.001), P. aeruginosa (20% vs. 32% vs. 58%, p<0.001) and other bacteria (14% vs 19% vs 25%, p=0.038). Median predicted FEV1 was statistically different among the groups (M:88% vs. MP:77% vs. P:72%, p<0.001) as well as the median Bronchiectasis Severity Index values (M:6 vs. MP:8 vs. P:9, p<0.001). Quality of life was significantly poorer in Group P vs. MP vs. M (QoL-B respiration score: 52 vs. 61 vs. 70, p<0.001). Differences in hospitalization rate (M: 10% vs P: 33%) and 3+ exacerbation/year (M 41% vs P 58%) were detected in follow up. The exclusion of COPD did not affect the results. Conclusion: Murray sputum chart is a valuable tool to assess disease severity and might be useful to predict clinical outcomes in Bx.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
